Tavalisse

Chemical Namefostamatinib disodium hexahydrate
Dosage FormTablet (oral; 100 mg, 150 mg)
Drug ClassKinase inhibitors
SystemBlood
CompanyRigel Pharmaceuticals
Approval Year2018

Indication

  • Tavalisse is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.
Last updated on 12/15/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Tavalisse (fostamatinib disodium hexahydrate) Prescribing Information2018Rigel Pharmaceuticals